Market Cap 449.50B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 18.01
Forward PE 17.21
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 5,324,000
Avg Vol 8,294,610
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 77%
Beta 0.38
Analysts Strong Sell
Price Target $202.35

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
ortega1963
ortega1963 Nov. 11 at 4:11 PM
$JNJ long
0 · Reply
MaxRamirez1087
MaxRamirez1087 Nov. 11 at 3:25 PM
$JNJ maintains defensive stability with a strong pharmaceutical and medtech pipeline supporting dividend reliability. AERT recently turned profitable in Q2 FY2026, reporting $17.36 M revenue and $0.64 M net income, highlighting momentum in its AI-led global delivery model. https://www.youtube.com/watch?v=d2BieklTnl4
0 · Reply
biolover
biolover Nov. 11 at 2:34 PM
$VKTX I never talk about $JNJ as potential Viking partner. But still believe Lilly q3 made a turmoil in several BP board rooms. With BL recent statement , and with JNJ seeing its MC a small piece of Lilly’s ( that used to be 1/4- of JNJ ) , everything is possible.
2 · Reply
moneybag888
moneybag888 Nov. 10 at 9:16 PM
$ARGX $JNJ $MRK $PFE @Biodro $70 to 100b?
0 · Reply
Stickingtrue
Stickingtrue Nov. 10 at 5:51 PM
0 · Reply
Stickingtrue
Stickingtrue Nov. 10 at 5:49 PM
0 · Reply
Nosi69420
Nosi69420 Nov. 10 at 5:48 PM
0 · Reply
Etrading
Etrading Nov. 10 at 5:46 PM
$JNJ what a nice push since $150S last 6 month while $PFE being POS..
0 · Reply
Indexing4
Indexing4 Nov. 10 at 5:43 PM
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Nov. 10 at 5:42 PM
🚀 $ASBP – Aspire Biopharma 💊 2-min heart attack aspirin ⚡ Accelerated FDA status 🌍 Strong interest at CPHI Frankfurt (Deva, Bayer, Key Pharma) 💥 Patent filed, $100B market potential 🔥 Low float + short squeeze potential Big moves coming, watch closely! $PFE $LLY $JNJ
0 · Reply
Latest News on JNJ
Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 4 days ago

Johnson & Johnson: Dividends Don't Lie


Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 5 days ago

Cramer's Mad Dash: Johnson & Johnson


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 10 days ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 13 days ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX


J&J Stock Can Fall

Oct 28, 2025, 9:25 AM EDT - 14 days ago

J&J Stock Can Fall


Johnson & Johnson Stock To $134?

Oct 22, 2025, 2:00 PM EDT - 19 days ago

Johnson & Johnson Stock To $134?


Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 12:36 PM EDT - 27 days ago

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript


J&J to spin off orthopedics business, raises full-year forecast

Oct 14, 2025, 6:26 AM EDT - 4 weeks ago

J&J to spin off orthopedics business, raises full-year forecast


ortega1963
ortega1963 Nov. 11 at 4:11 PM
$JNJ long
0 · Reply
MaxRamirez1087
MaxRamirez1087 Nov. 11 at 3:25 PM
$JNJ maintains defensive stability with a strong pharmaceutical and medtech pipeline supporting dividend reliability. AERT recently turned profitable in Q2 FY2026, reporting $17.36 M revenue and $0.64 M net income, highlighting momentum in its AI-led global delivery model. https://www.youtube.com/watch?v=d2BieklTnl4
0 · Reply
biolover
biolover Nov. 11 at 2:34 PM
$VKTX I never talk about $JNJ as potential Viking partner. But still believe Lilly q3 made a turmoil in several BP board rooms. With BL recent statement , and with JNJ seeing its MC a small piece of Lilly’s ( that used to be 1/4- of JNJ ) , everything is possible.
2 · Reply
moneybag888
moneybag888 Nov. 10 at 9:16 PM
$ARGX $JNJ $MRK $PFE @Biodro $70 to 100b?
0 · Reply
Stickingtrue
Stickingtrue Nov. 10 at 5:51 PM
0 · Reply
Stickingtrue
Stickingtrue Nov. 10 at 5:49 PM
0 · Reply
Nosi69420
Nosi69420 Nov. 10 at 5:48 PM
0 · Reply
Etrading
Etrading Nov. 10 at 5:46 PM
$JNJ what a nice push since $150S last 6 month while $PFE being POS..
0 · Reply
Indexing4
Indexing4 Nov. 10 at 5:43 PM
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Nov. 10 at 5:42 PM
🚀 $ASBP – Aspire Biopharma 💊 2-min heart attack aspirin ⚡ Accelerated FDA status 🌍 Strong interest at CPHI Frankfurt (Deva, Bayer, Key Pharma) 💥 Patent filed, $100B market potential 🔥 Low float + short squeeze potential Big moves coming, watch closely! $PFE $LLY $JNJ
0 · Reply
3DBuilds
3DBuilds Nov. 10 at 2:00 PM
0 · Reply
waterlock
waterlock Nov. 10 at 12:12 PM
$MGTX I find it interesting though. The company signed deals with Sanofi, J&J, Eli Lilly and $SNY and $JNJ are investors. Is Zandy collecting records LOL
1 · Reply
Iightning
Iightning Nov. 9 at 8:36 PM
1ightning® Options Trade Alert (Actionable) | Buy $JNJ Nov 14 $190 Call | Enter: $1.62 Exit: $2.90 | Profit: 79.20% ROI | https://1ightning.com
0 · Reply
stockanalysis_
stockanalysis_ Nov. 9 at 3:37 PM
Top-Rated Dividend Stocks: $XOM $JNJ $BAC $UNH $WFC Bookmark this page: https://stockanalysis.com/list/top-rated-dividend-stocks/?ref=saveontrading
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 9 at 3:32 AM
💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $190 Calls Scale in: $13.10- $16.01 Scale out: $50.93-$87.31 Profit Potential : 239% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
StratSoldier
StratSoldier Nov. 8 at 11:24 PM
$JNJ inside week #trading #theStrat
0 · Reply
biolover
biolover Nov. 8 at 5:32 PM
$JNJ $VKTX JNJ probably needs medical guy at the helm. It is slowly getting to be similar case to $MRK ( although with Merck Dean LI CMO who makes decision on BD ). But the Joaquin Duato guy lacks global view on human health issues. The Dominance in multiple myeloma may end as every company has assets now. And $ABBV is eating JNJ lunch in immunology. While revenues still good .. what is in pipeline not enough to continue leadership. $LLY ABBV and others will leap over JNJ Particularly when ABBV gets heavy in obesity as I expect.
0 · Reply
wwmeinc
wwmeinc Nov. 8 at 4:57 PM
$VKTX $JNJ ....Ask anything these days and something pops up that has a 50/50 chance of proceeding....also having lots of billions on the balance sheet allows for some real speculation...all based on the premise that $VKTX is next up on the B/O ladder...these LLM(Google) are helpful though....Looking forward to the next moves on the chess board that is this weight-loss/cardio sector...glta "Johnson & Johnson's primary weakness in the obesity sector is the lack of a blockbuster weight-loss drug in its portfolio, leaving it unable to directly compete with market leaders like Eli Lilly and Novo Nordisk. This has several negative consequences: " "Accelerated Development: JNJ's extensive resources and global commercial infrastructure could significantly speed up the development, clinical trials (e.g., cardiovascular outcomes trials), and commercialization of Viking's drugs, potentially bringing them to market faster than Viking could independently..."
0 · Reply
Suite510
Suite510 Nov. 8 at 1:56 PM
$KVUE $JNJ $SPX $SPY I should be at Goldman trading 😂 Texas Attorney General Ken Paxton asked a state judge on Thursday to block Kenvue (KVUE.N) from paying a nearly $400 million shareholder dividend this month, after suing the drugmaker for allegedly concealing risks to children from Tylenol
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 8 at 12:32 PM
Enter: $JNJ Calls Strike Price: $190 Expiry Date: NOV 28 2025 Buy in Price: $1.89 - $1.90 Sell Price: $4.14 Profit : +118% (Turn every $1 into $2.18) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
DidYouReadThis
DidYouReadThis Nov. 7 at 7:19 PM
$JNJ friends, can someone please share a bookmarked calculator for estimating the value of a small pharma company pre vs post FDA approval? Thank you!
0 · Reply
Twills08
Twills08 Nov. 7 at 6:59 PM
$ITRM Sticking to my original prediction of a $5 BO. The longer this has to gain traction the higher the BO multiple. $6-10 is definitely in play with interval developments. I expect EC to show increased national traction from insurance co’s and uptrending script numbers, likely modest as it gains momentum. BO can occur at any time. The picture at large is highly suggestive of it. The easiest play on the national stage for Fishman is to hand it off to $INVA or $PFE (who humorously is going to lose out on another play bc of lowballing). $MRK and $JNJ are possible suitors. For these folks, this is spare change in their underwear drawer.
3 · Reply